Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Open Label, Multicenter Study to Access the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients With Advanced Solid Tumors

NCT04259450 is registered in ClinicalTrials.gov with Affimed GmbH as lead sponsor.

NCT NCT04259450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04259450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Open Label, Multicenter Study to Access the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients With Advanced Solid Tumors
Lead sponsor
Affimed GmbH
Phase
Phase 1/2
Overall status
Terminated
Start date
April 7, 2020
Completion date
June 24, 2024
Enrollment
85 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor